Oral renin inhibitor needs further testing

Australian researchers investigated whether the antihypertensive aliskiren — which is not PBS listed — could slow progression of coronary atherosclerosis in patients whose blood pressure was considered optimally controlled.

A 300mg daily dose for two years was compared with placebo in 613 participants with coronary artery disease, systolic blood pressure between 125 and 139mmHg and two additional cardiovascular risk factors.

No statistical difference was found in the primary efficacy parameter - the change in percent atheroma volume